Skip to content

Efficacy of exoskeleton technology based on corticomuscular coherence: a randomized controlled trial

Research on the Mechanism of Cortico-Muscular Bidirectional Neural Pathway Remodeling in Stroke

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400094656
Enrollment
Unknown
Registered
2024-12-25
Start date
2023-10-19
Completion date
Unknown
Last updated
2025-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stroke

Interventions

Control group:The subjects received conventional rehabilitation treatment. Both groups underwent a lower limb functional assessment of BBS and objective data collection before and after the interventi
Eexperimental group:The experimental group used exoskeleton robot walking training on the basis of conventional rehabilitation therapy:The unilateral lower limb exoskeleton robot developed by the grou

Sponsors

The Fifth Affiliated Hospital of Zhengzhou University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 79 Years

Inclusion criteria

Inclusion criteria: 1. All meet the diagnostic criteria for stroke set by the 4th National Academic Conference on Cerebrovascular Diseases and confirmed by cranial CT or MRI. 2. The number of onset is unlimited, unilateral injury, stable condition, and the duration of the disease is not more than 1 year. 3. Age 18-79 years old. 4. Lower limb Brunnstrom staging: stage II - stage V; sitting and standing balance function at grade 1 and above. 5. Clear mind, cooperation in physical examination, can accept two steps and more movement instructions, MoCA18. 6. Satisfy the needs of wearing exoskeleton: height 1.5-1.9m weight <= 100kg. 7. No other related robotics training in the past 3 months. 8. Able to understand the purpose of the study, the patient himself or her family signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Recent lower limb fracture or osteoporosis (Screening according to the recommended method of primary osteoporosis diagnosis and treatment guidelines. 2. Those with localised skin injuries or localised pressure sores. 3. Those with vital organ failure or other serious diseases. 4. Female subjects with positive pregnancy test during pregnancy or lactation or screening. 5. Participated in other drug or medical device clinical trials within 3 months prior to enrolment. 6. Suffering from other neurological diseases. Such as cerebral palsy, spinal cord injury.

Design outcomes

Primary

MeasureTime frame
Eeg - EMG acquisition;the Berg Balance Scale,BBS;Fugl-Meyer assessment scale,FMA;Activity of Daily Living,ADL;

Countries

China

Contacts

Public ContactAnqin Dong

The Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou City, Henan Province, China

anqindong@163.com+86 187 0380 9920

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026